However, just as tumour imaging has seen the introduction of several more specific PET-radiopharmaceuticals with alternative isotopes (e.g., prostate-specific membrane antigen (PSMA)-imaging for prostate cancer and various radiopharmaceuticals for neuroendocrine tumours), more specific radiopharmaceuticals are also being investigated for infection and inflammation. The gene discussed is FOLH1; the disease is infection.